STAGE IIIB LUNG CANCER AJCC V8

This study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation, and continuing it afterward, helps people with stage III lung cancer that cannot be surgically removed live longer and keep the cancer from coming back. About 660 adults with newly diagn…

This study is for people with non-small cell lung cancer who have had chemotherapy and surgery. It tests whether adding a drug called AZD6738 to the immunotherapy drug durvalumab can help keep the cancer from coming back longer than durvalumab alone. About 630 adults with stage I…

This phase 3 study tests whether starting with immunotherapy alone (pembrolizumab) and adding chemotherapy only if the cancer worsens is better than starting with both immunotherapy and chemotherapy together for advanced non-squamous lung cancer. About 600 patients with stage IV …

This early-phase trial studies the safety and effectiveness of combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy for patients with stage II or III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this combinatio…

This study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer that has responded to initial chemotherapy. The goal is to find the safest dose and see if the combination help…

This study tests a combination of the CIMAvax vaccine and nivolumab (an immunotherapy drug) in people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to find the best dose and see if the combination helps control tumor growth and improve sur…

This study tests whether a lung cancer drug called atezolizumab can be safely given as a shot under the skin at home, with doctors monitoring patients through video calls. It involves 5 adults with non-small cell lung cancer. The goal is to see if this home-based approach is prac…

This study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus lo…

This study compares two treatments for lung tumors: microwave ablation (using heat to kill cancer cells) and surgical wedge resection (removing a small piece of lung). It includes adults with non-small cell lung cancer, sarcoma, or colorectal cancer that has spread to the lungs. …

This study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…

This early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses immune cells from donated umbilical cord blood that are genetically modified to better recognize and attack cance…

This study tests two drugs together—trametinib and pembrolizumab—in people with advanced non-small cell lung cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the cancer's growth. About 37 participants will receive the treatment, …

This early-phase trial tests the safety and best dose of a new drug called minnelide when combined with the standard drug osimertinib for people with advanced EGFR-mutant non-small cell lung cancer. Only 8 participants are enrolled. The goal is to find side effects and the right …

This study tests two drugs together for people with small cell lung cancer or other high-grade neuroendocrine cancers that have already been treated. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the immune system attack the tumor. The goal is to …

This early-stage trial tests a drug called NBTXR3 that makes radiation more effective at killing cancer cells. It is for people with non-small cell lung cancer that has returned and cannot be removed with surgery. The study aims to find the safest dose and see if combining the dr…

This early-phase study tests a combination of two drugs, brigatinib and bevacizumab, in people with a specific type of lung cancer (ALK-positive) that has spread or returned after prior ALK-directed therapy. The main goals are to find the best dose and check for side effects. Onl…

This study tests a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The two drugs, LY3295668 and osimertinib, work by blocking enzymes that help cancer cells grow. The goal is to find the safest dose and see if…

This phase 2 study tests a new drug (pevonedistat) combined with two standard chemotherapies (carboplatin and paclitaxel) in 27 adults with advanced non-small cell lung cancer that has not responded to immunotherapy. The goal is to see if this combination can shrink or control th…

This study looks at whether adding radiation therapy to standard immunotherapy (with or without chemo) helps people with advanced non-small cell lung cancer that lacks the PD-L1 marker. About 427 adults with stage IIIB, IIIC, or IV cancer will be randomly assigned to get either t…

This study tests whether adding N-803 (a natural killer cell booster) to pembrolizumab (an immunotherapy) can help shrink or stabilize advanced non-small cell lung cancer in patients whose previous immunotherapy stopped working. About 82 participants will receive either the combo…

This study looks at whether a drug called anamorelin can help improve appetite and prevent weight loss in people with advanced non-small cell lung cancer who have lost their appetite and are losing weight. About 25 participants will take either the drug or a placebo and share the…

This study tests an online program designed to help women with lung cancer feel more supported and less distressed during treatment. The program uses techniques like mindfulness and emotional processing to improve social well-being. About 70 women with stage I-IV non-small cell l…

This study looks at whether updating radiation treatment plans at set times (adaptive planning) can lower side effects like lung inflammation in people with stage II-IV non-small cell lung cancer. About 34 participants will receive standard radiation and immunotherapy, but their …

This study tests a telehealth self-management program for people who have finished treatment for early-stage lung or colorectal cancer. The program provides coaching on follow-up care, communication with doctors, and quality of life. Researchers will compare outcomes between part…

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with fears about their future. About 42 participants will try the program, which includes sessions and home activities. The goal is to see if the program is practical and he…

This early-stage study tests whether giving a single, very focused dose of radiation after lung cancer surgery is safe and causes fewer side effects than standard weeks-long radiation. It involves 50 adults with non-small cell lung cancer who had surgery but still have cancer cel…

This study screens up to 8300 people with early-stage non-small cell lung cancer (stages IB to IIIA) whose tumor has been or will be removed by surgery. Researchers analyze the tumor's genes to find specific mutations, which helps doctors choose the most effective targeted therap…

This study aims to find out why some cancer patients develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track over 1,300 people with breast, lung, or ovarian cancer to see how age, gender, and other factors affect their risk. …